Andres Y. Maldonado has given his Buy rating due to a combination of factors, primarily centered around the promising clinical data for I-MAB’s lead asset, givastomig. The recent Phase 1 monotherapy results presented at a major conference highlighted an 18% objective response rate in heavily pre-treated metastatic gastric cancer patients, showcasing the drug’s potential as a best-in-class treatment. The durability of responses, with some lasting up to 33 months, and a favorable safety profile further bolster confidence in its clinical prospects.
Despite the positive clinical outlook, Maldonado acknowledges the strategic uncertainties introduced by I-MAB’s ongoing corporate transformation. The company’s shift towards a new brand and business model, along with a planned IPO in Hong Kong, could impact capital allocation and focus. However, the analyst remains optimistic about givastomig’s role as a primary value driver, while also noting the need for careful management of resources to ensure the company’s oncology focus remains intact.

Y. Maldonado covers the Healthcare sector, focusing on stocks such as Candel Therapeutics, Protara Therapeutics, and Corbus Pharmaceuticals. According to TipRanks, Y. Maldonado has an average return of 23.5% and a 53.59% success rate on recommended stocks.

In another report released on October 24, BTIG also reiterated a Buy rating on the stock with a $9.00 price target.